BR112022005224A2 - Use of fgfr inhibitors in cancers genetically altered by fgfr to improve patient response to immune checkpoint inhibitors in sequential treatment settings - Google Patents

Use of fgfr inhibitors in cancers genetically altered by fgfr to improve patient response to immune checkpoint inhibitors in sequential treatment settings

Info

Publication number
BR112022005224A2
BR112022005224A2 BR112022005224A BR112022005224A BR112022005224A2 BR 112022005224 A2 BR112022005224 A2 BR 112022005224A2 BR 112022005224 A BR112022005224 A BR 112022005224A BR 112022005224 A BR112022005224 A BR 112022005224A BR 112022005224 A2 BR112022005224 A2 BR 112022005224A2
Authority
BR
Brazil
Prior art keywords
fgfr
inhibitors
genetically altered
cancers
immune checkpoint
Prior art date
Application number
BR112022005224A
Other languages
Portuguese (pt)
Inventor
Elena Santiago-Walker Ademi
Enrique Zudaire
Raluca Verona
S Shalaby Waleed
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of BR112022005224A2 publication Critical patent/BR112022005224A2/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered

Abstract

uso de inibidores de fgfr em cânceres alterados geneticamente por fgfr para melhorar a resposta do paciente a inibidores de ponto de verificação imune em configurações de tratamento sequenciais. a presente invenção refere-se a um método de tratar câncer em um paciente compreendendo administrar um inibidor de ponto de verificação ao paciente, em que o paciente foi diagnosticado com um câncer geneticamente alterado por fgfr e foi pré-tratado com um inibidor de fgfr, tal como erdafitinibe.use of fgfr inhibitors in cancers genetically altered by fgfr to improve patient response to immune checkpoint inhibitors in sequential treatment settings. the present invention relates to a method of treating cancer in a patient comprising administering a checkpoint inhibitor to the patient, wherein the patient has been diagnosed with a cancer genetically altered by fgfr and has been pre-treated with a fgr inhibitor, such as erdafitinib.

BR112022005224A 2019-09-26 2020-09-25 Use of fgfr inhibitors in cancers genetically altered by fgfr to improve patient response to immune checkpoint inhibitors in sequential treatment settings BR112022005224A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962906517P 2019-09-26 2019-09-26
PCT/EP2020/076999 WO2021058798A1 (en) 2019-09-26 2020-09-25 Use of fgfr inhibitors in fgfr-genetically altered cancers to enhance patient response to immune checkpoint inhibitors in sequential treatment settings

Publications (1)

Publication Number Publication Date
BR112022005224A2 true BR112022005224A2 (en) 2022-06-14

Family

ID=72665262

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112022005224A BR112022005224A2 (en) 2019-09-26 2020-09-25 Use of fgfr inhibitors in cancers genetically altered by fgfr to improve patient response to immune checkpoint inhibitors in sequential treatment settings

Country Status (12)

Country Link
US (1) US20220348662A1 (en)
EP (1) EP4034118A1 (en)
JP (1) JP2022550110A (en)
KR (1) KR20220070243A (en)
CN (1) CN114466662A (en)
AU (1) AU2020352668A1 (en)
BR (1) BR112022005224A2 (en)
CA (1) CA3151395A1 (en)
IL (1) IL291594A (en)
JO (1) JOP20220073A1 (en)
MX (1) MX2022003686A (en)
WO (1) WO2021058798A1 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023044119A1 (en) * 2021-09-20 2023-03-23 Droplet Biosciences, Inc. Lymphatic fluid for diagnostics

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201007286D0 (en) 2010-04-30 2010-06-16 Astex Therapeutics Ltd New compounds
UA122564C2 (en) 2014-09-26 2020-12-10 Янссен Фармацевтика Нв Use of fgfr mutant gene panels in identifying cancer patients that will be responsive to treatment with an fgfr inhibitor
SG11201706727XA (en) * 2015-02-19 2017-09-28 Bioclin Therapeutics Inc Methods, compositions, and kits for treatment of cancer
RU2021107536A (en) * 2015-11-23 2021-07-02 Файв Прайм Терапьютикс, Инк. FGFR2 INHIBITORS SEPARATELY OR IN COMBINATION WITH IMMUNOSTIMULATING AGENTS IN THE TREATMENT OF CANCER

Also Published As

Publication number Publication date
US20220348662A1 (en) 2022-11-03
EP4034118A1 (en) 2022-08-03
JOP20220073A1 (en) 2023-01-30
KR20220070243A (en) 2022-05-30
IL291594A (en) 2022-05-01
JP2022550110A (en) 2022-11-30
CN114466662A (en) 2022-05-10
CA3151395A1 (en) 2021-04-01
MX2022003686A (en) 2022-04-25
AU2020352668A1 (en) 2022-03-31
WO2021058798A1 (en) 2021-04-01

Similar Documents

Publication Publication Date Title
MX2022007472A (en) Use of plinabulin in combination with immune checkpoint inhibitors.
CL2018000853A1 (en) Combination therapy of bromodomain inhibitors and blocking immune control points to treat cancer.
EA201991555A1 (en) COMPOSITIONS AND METHODS FOR STRENGTHENING OR INCREASING PRODUCTS IFN I TYPE
MX2023001527A (en) Compounds with ferroptosis inducing activity and methods of their use.
CR20170014A (en) METHODS TO TREAT CANCER WITH TIGIT INHIBITORS AND AGENTS AGAINST CANCER
BR112017018234A2 (en) pd-1 / pd-l1 inhibitors for cancer treatment
NI201400095A (en) METHODS FOR THE TREATMENT OF NON-SMALL CELL LUNG CANCER USING COMBINED THERAPY OF INHIBITOR TOR KINASE.
BR112016017700A2 (en) method for treating a cancer in an individual, drug, kit, method, use or kit, and, method, drug or kit
MX2021012977A (en) Treatment of cancer with tg02.
MX370573B (en) Gla monotherapy for use in cancer treatment.
MX2022012424A (en) Treatment of fragile x syndrome with cannabidiol.
MX2018006674A (en) Cancer treatment using 2-deoxy-2-fluoro-l-fucose in combination with a checkpoint inhibitor.
MX2021000847A (en) Methods of treating cancer with pi3k inhibitor, gdc-0077.
MX2019013862A (en) Combination therapy.
DOP2019000019A (en) METHODS TO TREAT PROSTATE CANCER
BR112015026247A2 (en) methods for cancer treatment using tor kinase inhibitor combination therapy
PH12019502316A1 (en) Combination cancer immunotheraphy with pentaaza macrocyclic ring complex
CO2022000481A2 (en) enzyme inhibitors
MX2020010269A (en) Methods of treating ulcerative colitis.
CL2022001794A1 (en) Combination therapy comprising a2a/a2b and pd-1/pd-11 inhibitors.
MX2021013354A (en) Methods of treating and/or preventing actinic keratosis.
BR112019008241A2 (en) treatment of nodular prurigo
CL2019001002A1 (en) Methods and compositions for immunotherapy by tusc2.
BR112022005224A2 (en) Use of fgfr inhibitors in cancers genetically altered by fgfr to improve patient response to immune checkpoint inhibitors in sequential treatment settings
MX2018001493A (en) Gdf-15 as a haematological toxicity biomarker.